Chapman Michael P, Moore Ernest E, Moore Hunter B, Gonzalez Eduardo, Gamboni Fabia, Chandler James G, Mitra Sanchayita, Ghasabyan Arsen, Chin Theresa L, Sauaia Angela, Banerjee Anirban, Silliman Christopher C
From the Department of Surgery (M.P.C., E.E.M, H.B.M, E.G., F.G.S., J.G.C., S.M., A.G., T.L.C., A.S., A.B., C.C.S.), University of Colorado-Denver; Department of Surgery, Denver Health Medical Center (M.P.C., E.E.M., H.B.M. E.G., J.G.C. A.G., T.L.C., A.S.); Department of Surgery, Georgia Regents University (M.P.C.); Department of Hematology and Oncology (C.C.S.), Children's Hospital Colorado; and Bonfils Blood Center (C.C.S.), Denver, Colorado.
J Trauma Acute Care Surg. 2016 Jan;80(1):16-23; discussion 23-5. doi: 10.1097/TA.0000000000000885.
Trauma-induced coagulopathy (TIC) is associated with a fourfold increased risk of mortality. Hyperfibrinolysis is a component of TIC, but its mechanism is poorly understood. Plasminogen activation inhibitor (PAI-1) degradation by activated protein C has been proposed as a mechanism for deregulation of the plasmin system in hemorrhagic shock, but in other settings of ischemia, tissue plasminogen activator (tPA) has been shown to be elevated. We hypothesized that the hyperfibrinolysis in TIC is not the result of PAI-1 degradation but is driven by an increase in tPA, with resultant loss of PAI-1 activity through complexation with tPA.
Eighty-six consecutive trauma activation patients had blood collected at the earliest time after injury and were screened for hyperfibrinolysis using thrombelastography (TEG). Twenty-five hyperfibrinolytic patients were compared with 14 healthy controls using enzyme-linked immunosorbent assays for active tPA, active PAI-1, and PAI-1/tPA complex. Blood was also subjected to TEG with exogenous tPA challenge as a functional assay for PAI-1 reserve.
Total levels of PAI-1 (the sum of the active PAI-1 species and its covalent complex with tPA) are not significantly different between hyperfibrinolytic trauma patients and healthy controls: median, 104 pM (interquartile range [IQR], 48-201 pM) versus 115 pM (IQR, 54-202 pM). The ratio of active to complexed PAI-1, however, was two orders of magnitude lower in hyperfibrinolytic patients than in controls. Conversely, total tPA levels (active + complex) were significantly higher in hyperfibrinolytic patients than in controls: 139 pM (IQR, 68-237 pM) versus 32 pM (IQR, 16-37 pM). Hyperfibrinolytic trauma patients displayed increased sensitivity to exogenous challenge with tPA (median LY30 of 66.8% compared with 9.6% for controls).
Depletion of PAI-1 in TIC is driven by an increase in tPA, not PAI-1 degradation. The tPA-challenged TEG, based on this principle, is a functional test for PAI-1 reserves. Exploration of the mechanism of up-regulation of tPA is critical to an understanding of hyperfibrinolysis in trauma.
Prognostic and epidemiologic study, level II.
创伤性凝血病(TIC)与死亡风险增加四倍相关。高纤维蛋白溶解是TIC的一个组成部分,但其机制尚不清楚。活化蛋白C降解纤溶酶原激活物抑制剂(PAI-1)被认为是失血性休克中纤溶酶系统失调的一种机制,但在其他缺血情况下,组织纤溶酶原激活物(tPA)已被证明升高。我们假设TIC中的高纤维蛋白溶解不是PAI-1降解的结果,而是由tPA增加驱动的,tPA与PAI-1结合导致PAI-1活性丧失。
86例连续创伤激活患者在受伤后最早时间采集血液,使用血栓弹力图(TEG)筛查高纤维蛋白溶解。25例高纤维蛋白溶解患者与14例健康对照者进行比较,采用酶联免疫吸附测定法检测活性tPA、活性PAI-1和PAI-1/tPA复合物。血液还接受外源性tPA激发的TEG检测,作为PAI-1储备的功能检测。
高纤维蛋白溶解创伤患者与健康对照者的PAI-1总水平(活性PAI-1及其与tPA的共价复合物之和)无显著差异:中位数分别为104 pM(四分位间距[IQR],48 - 201 pM)和115 pM(IQR,54 - 202 pM)。然而,高纤维蛋白溶解患者中活性PAI-1与复合PAI-1的比值比对照组低两个数量级。相反,高纤维蛋白溶解患者的总tPA水平(活性 + 复合物)显著高于对照组:139 pM(IQR,68 - 237 pM)对32 pM(IQR,16 - 37 pM)。高纤维蛋白溶解创伤患者对外源性tPA激发的敏感性增加(中位LY30为66.8%,而对照组为9.6%)。
TIC中PAI-1的消耗是由tPA增加驱动的,而非PAI-1降解。基于这一原理的tPA激发TEG是PAI-1储备的功能检测。探索tPA上调机制对于理解创伤中的高纤维蛋白溶解至关重要。
预后和流行病学研究,II级。